Aerovate Therapeutics, Inc.
NASDAQ: AVTE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy P. Noyes
- Employees
- 4
- Headquarters
- Waltham, United States
- IPO year
- 2021
- Market cap
- $77.7M
- Website
- https://aerovatetx.com
Loading AVTE…
Loading profile data…Frequently asked questions about AVTE
What does Aerovate Therapeutics, Inc. (AVTE) do?
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoi...
Where does AVTE trade?
Aerovate Therapeutics, Inc. (AVTE) trades on the NASDAQ Global Market.
What sector is AVTE in?
Aerovate Therapeutics, Inc. (AVTE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aerovate Therapeutics, Inc.?
Timothy P. Noyes is the chief executive officer of Aerovate Therapeutics, Inc. (AVTE).
Where is Aerovate Therapeutics, Inc. headquartered?
Aerovate Therapeutics, Inc. is headquartered in United States.
Does AVTE pay a dividend?
Aerovate Therapeutics, Inc. (AVTE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVTE go public?
Aerovate Therapeutics, Inc. (AVTE) completed its initial public offering in 2021.